Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$760,760
+$480,003 QoQ
Shares Held
13,982
+113.6% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#368
of 739 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MAI Capital Management holds $23,665,100 across 54 Biotechnology names. EXEL ranks #8 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,715 | $4,187,071 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,638 | $2,800,563 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
49,160 | $1,264,394 | |
| 4 | INCY |
Incyte Corp
|
10,126 | $1,147,882 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
56,130 | $1,046,824 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
5,147 | $963,929 | |
| 7 | LGND |
Ligand Pharmaceuticals Inc
|
2,963 | $936,574 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
13,982 | $760,760 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $760,760 | 13,982 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $280,757 | 6,546 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $157,437 | 3,592 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $146,615 | 3,550 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $166,754 | 3,783 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $40,427 | 1,095 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $35,397 | 1,063 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||